Literature DB >> 2712542

Comparative in vitro activities of six new fluoroquinolones and other oral antimicrobial agents against Campylobacter pylori.

A E Simor1, S Ferro, D E Low.   

Abstract

The in vitro susceptibilities of 56 clinical isolates of Campylobacter pylori to six new fluoroquinolones and other oral antimicrobial agents were determined by an agar dilution technique. Ciprofloxacin was the most active of the fluoroquinolones (MIC for 90% of strains tested [MIC90], 0.05 microgram/ml). Other fluoroquinolones had variable activities, although most isolates were moderately susceptible to fleroxacin (MIC90, 4 micrograms/ml) and lomefloxacin (MIC90, 4 micrograms/ml).

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2712542      PMCID: PMC171430          DOI: 10.1128/AAC.33.1.108

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

2.  Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment.

Authors:  E A Rauws; W Langenberg; H J Houthoff; H C Zanen; G N Tytgat
Journal:  Gastroenterology       Date:  1988-01       Impact factor: 22.682

3.  Failure of ciprofloxacin to eradicate Campylobacter pylori from the stomach.

Authors:  J W Stone; R Wise; I A Donovan; J Gearty
Journal:  J Antimicrob Chemother       Date:  1988-07       Impact factor: 5.790

Review 4.  The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.

Authors:  D C Hooper; J S Wolfson
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

5.  Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents.

Authors:  C A McNulty; J Dent; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

6.  Effect of treatment on Campylobacter pylori in peptic disease: a randomised prospective trial.

Authors:  H Humphreys; S Bourke; C Dooley; D McKenna; B Power; C T Keane; E C Sweeney; C O'Moráin
Journal:  Gut       Date:  1988-03       Impact factor: 23.059

7.  Comparative susceptibilities of Campylobacter pylori to norfloxacin and other agents.

Authors:  D L Shungu; D R Nalin; R H Gilman; H H Gadebusch; A T Cerami; C Gill; B Weissberger
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

8.  In vitro synergistic activity between bismuth subcitrate and various antimicrobial agents against Campylobacter pyloridis (C. pylori).

Authors:  D L Van Caekenberghe; J Breyssens
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

Review 9.  Gastric Campylobacter-like organisms, gastritis, and peptic ulcer disease.

Authors:  M J Blaser
Journal:  Gastroenterology       Date:  1987-08       Impact factor: 22.682

10.  Pyloric Campylobacter infection and gastroduodenal disease.

Authors:  B J Marshall; D B McGechie; P A Rogers; R J Glancy
Journal:  Med J Aust       Date:  1985-04-15       Impact factor: 7.738

View more
  11 in total

1.  Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori.

Authors:  T Iwahi; H Satoh; M Nakao; T Iwasaki; T Yamazaki; K Kubo; T Tamura; A Imada
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

2.  In vitro selection of resistant Helicobacter pylori.

Authors:  C E Haas; D E Nix; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

3.  Evaluation of nitrofurantoin combination therapy of metronidazole-sensitive and -resistant Helicobacter pylori infections in mice.

Authors:  P J Jenks; R L Ferrero; J Tankovic; J M Thiberge; A Labigne
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

4.  Antibacterial properties of lansoprazole alone and in combination with antimicrobial agents against Helicobacter pylori.

Authors:  M Nakao; M Tada; K Tsuchimori; M Uekata
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-05       Impact factor: 3.267

Review 5.  Fleroxacin clinical pharmacokinetics.

Authors:  A E Stuck; D K Kim; F J Frey
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

6.  Antimicrobial susceptibility testing of 230 Helicobacter pylori strains: importance of medium, inoculum, and incubation time.

Authors:  S H Hartzen; L P Andersen; A Bremmelgaard; H Colding; M Arpi; J Kristiansen; T Justesen; F Espersen; N Frimodt-Møller; O Bonnevie
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

Review 7.  Pefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J P Gonzalez; J M Henwood
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

Review 8.  Quinolones and the gastrointestinal tract.

Authors:  B E Murray
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

Review 9.  Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.

Authors:  J A Balfour; P A Todd; D H Peters
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

10.  Inhibition of nanobacteria by antimicrobial drugs as measured by a modified microdilution method.

Authors:  N Cíftçíoglu; M A Miller-Hjelle; J T Hjelle; E O Kajander
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.